UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017647
Receipt number R000020434
Scientific Title Efficacy of duloxetine for cancer patients with neuropathic pain: Doubleblind, Randomized, Placebo controlled, exploratory trial
Date of disclosure of the study information 2015/05/21
Last modified on 2018/05/23 10:51:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of duloxetine for cancer patients with neuropathic pain: Doubleblind, Randomized, Placebo controlled, exploratory trial

Acronym

Efficacy of duloxetine for cancer patients with neuropathic pain: Doubleblind, Randomized, Placebo controlled, exploratory trial

Scientific Title

Efficacy of duloxetine for cancer patients with neuropathic pain: Doubleblind, Randomized, Placebo controlled, exploratory trial

Scientific Title:Acronym

Efficacy of duloxetine for cancer patients with neuropathic pain: Doubleblind, Randomized, Placebo controlled, exploratory trial

Region

Japan


Condition

Condition

Cancer Pain

Classification by specialty

Hematology and clinical oncology Psychosomatic Internal Medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to assess the efficacy and safety of the addition of duloxetine for cancer patients with neuropathic pain that are non-responsive or intolerant to gabapentinoids.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Pain NRS (BPI-item4, 24-hour average intensity of global pain)on Day10

Key secondary outcomes

Hospital anxiety and depression scale, Short-Form Mcgill Pain Questionnaire 2, European Organization for Research and Treatment of Cancer Quority of Life Questionnaire Core 15 palliative, Pain Catastrophizing Scale, Adverse Events, Rescue dose, Pain NRS on Day10 by subgroups (nonresponsive or intolerant to gabapentinoids)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Duloxetine Group
Treatment Period: 10 days (titration on day 3)
Dose: Duloxetine 20-40mg/day every morning

Interventions/Control_2

Placebo Group
Treatment Period: 10 days (titration on day 3)
Dose: Placebo 1cap-2cap/day every morning

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Cancer patients with neuropathic pain
2) Regularly scheduled systemic opioid therapy with insufficient analgesia
3) Non-responsive or intolerant to gabapentinoids
4) HADS<20
5) Age >= 20
6) Pain NRS(BPI item-4) >= 4
7) Creatinine clearance < 60 ml/min
8) AST<100 IU/L,ALT<100 IU/L,T-bil<2.0 mg/dl
9) Expected at least one month survival
10) Written informed consent

Key exclusion criteria

1) Chemotherapy-induced Peripheral Neuropathy
2) Progressive paralysis
3) Allergy to duloxetine
4) Depression
5) Patients who changed analgesic adjuvant agents within 2 days
6) Drug dependence or abuse
7) Uncontrolled psychiatric disease
8) Pregnancy or lactating patients
9) Patients who are judged as inadequate to participate to the trial due to other reasons by the doctor.

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiromichi Matsuoka

Organization

Kinki University, Faculty of Medicine

Division name

Department of Psychosomatic Medicine

Zip code


Address

377-2, Ohno-higashi, Osakasayama City, Osaka, 589-8511

TEL

072-366-0221

Email

matsuoka_h@med.kindai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiromichi Matsuoka

Organization

Kinki University, Faculty of Medicine

Division name

Department of Psychosomatic Medicine

Zip code


Address

377-2, Ohno-higashi, Osakasayama City, Osaka, 589-8511

TEL

072-366-0221

Homepage URL


Email

matsuoka_h@med.kindai.ac.jp


Sponsor or person

Institute

Japan Agency for Medical Research and Development

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

近畿中央胸部疾患センター(大阪府)
奈良県立医科大学附属病院(奈良県)
国立がん研究センター東病院(千葉県)
国立がん研究センター中央病院(東京都)
神戸大学医学部附属病院(兵庫県)
兵庫県立尼崎総合医療センター(兵庫県)
和泉市立病院(大阪府)
名古屋大学医学部附属病院(愛知県)
近畿大学医学部堺病院(大阪府)
近畿大学医学部附属病院(大阪府)
兵庫県立加古川医療センター(兵庫県)
関西医科大学(大阪府)
堺市立総合医療センター(大阪府)


Other administrative information

Date of disclosure of the study information

2015 Year 05 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 02 Month 26 Day

Date of IRB


Anticipated trial start date

2015 Year 07 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 05 Month 21 Day

Last modified on

2018 Year 05 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020434


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name